39,240 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by F m Investments LLC

F m Investments LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) in the 4th quarter, HoldingsChannel.com reports. The firm bought 39,240 shares of the company’s stock, valued at approximately $3,213,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TARS. Deep Track Capital LP grew its position in Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after buying an additional 1,250,000 shares in the last quarter. M&T Bank Corp grew its position in Tarsus Pharmaceuticals by 11,730.0% during the fourth quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after buying an additional 433,424 shares in the last quarter. MPM Bioimpact LLC purchased a new position in Tarsus Pharmaceuticals during the second quarter worth about $13,834,000. TimesSquare Capital Management LLC purchased a new position in Tarsus Pharmaceuticals during the third quarter worth about $15,898,000. Finally, Qube Research & Technologies Ltd grew its position in Tarsus Pharmaceuticals by 86.1% during the second quarter. Qube Research & Technologies Ltd now owns 459,436 shares of the company’s stock worth $18,612,000 after buying an additional 212,592 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Guggenheim boosted their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. HC Wainwright restated a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Insider Transactions at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 4,174 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the transaction, the insider directly owned 35,028 shares in the company, valued at approximately $2,346,876. This represents a 10.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Bryan Wahl sold 4,231 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the transaction, the general counsel owned 63,959 shares of the company’s stock, valued at $4,285,253. The trade was a 6.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,391 shares of company stock valued at $5,432,035 over the last quarter. 8.97% of the stock is owned by company insiders.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus reported Q1 EPS of -$0.16, beating expectations for a -$0.40 loss, and revenue of $162.05 million, above the $149.60 million consensus. Article Title
• Positive Sentiment: The company said Q1 XDEMVY net product sales topped $145 million, up more than 85% year over year, and reaffirmed 2026 guidance of $670 million to $700 million in XDEMVY sales. Article Title
• Neutral Sentiment: Management also highlighted broader business momentum, including stronger prescribing trends and the start of a Phase 2 Lyme disease prevention trial for TP-05. Article Title
• Neutral Sentiment: LifeSci Capital and HC Wainwright mostly kept bullish ratings on Tarsus, but several firms slightly lowered near-term EPS estimates after the report, which could temper enthusiasm. Article Title
• Negative Sentiment: Lifescis Capital cut Q1, Q2, Q3 and FY2026 EPS estimates, and HC Wainwright trimmed FY2027-FY2029 estimates slightly, reflecting continued losses in the near term despite long-term optimism. Article Title

Tarsus Pharmaceuticals Price Performance

TARS opened at $61.21 on Friday. The stock has a 50-day moving average price of $68.72 and a 200-day moving average price of $71.87. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The company has a current ratio of 3.74, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $2.63 billion, a P/E ratio of -53.69 and a beta of 0.52.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The firm had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. Equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.